Page 66 - GPD-3-2

Gene & Protein in Disease TOPK: Target for lung cancer treatment

doi: 10.1042/bsr20181692 doi: 10.1002/mco2.105
41. Fan X, Duan Q, Ke C, et al. Cefradine blocks solar-ultraviolet 52. Wang P, Li T, Fang L, Chen D, Qi H, Gu C. UPF1 regulates
induced skin inflammation through direct inhibition FOXO1 protein expression by promoting PBK transcription
of T-LAK cell-originated protein kinase. Oncotarget. in non-small cell lung cancer. Biochem Biophys Res Commun.
2016;7(17):24633-24645. 2023;666:10-20.
doi: 10.18632/oncotarget.8260 doi: 10.1016/j.bbrc.2023.05.001
42. Zou L, Gao Z, Zeng F, et al. Sulfasalazine suppresses thyroid 53. Park JH, Park SA, Lee YJ, Park HW, Oh SM. PBK attenuates
cancer cell proliferation and metastasis through T-cell paclitaxel-induced autophagic cell death by suppressing p53
originated protein kinase. Oncol Lett. 2019;18(4):3517-3526. in H460 non-small-cell lung cancer cells. FEBS Open Bio.
2020;10(5):937-950.
doi: 10.3892/ol.2019.10721
doi: 10.1002/2211-5463.12855
43. Kang NJ, Lee KW, Kim BH, et al. Coffee phenolic
phytochemicals suppress colon cancer metastasis by targeting 54. Juloori A, Vokes EE. Beyond PACIFIC: Uncharted waters.
MEK and TOPK. Carcinogenesis. 2011;32(6):921-928. J Thorac Oncol. 2021;16(5):715-718.
doi: 10.1093/carcin/bgr022 doi: 10.1016/j.jtho.2021.02.006
44. Yang J, Yuan D, Xing T, et al. Ginsenoside Rh2 inhibiting 55. Tan B, Zhang J, Wang W, Ma H, Yang Y. Tumor-suppressive
HCT116 colon cancer cell proliferation through blocking E3 ubiquitin ligase CHIP inhibits the PBK/ERK axis to
PDZ-binding kinase/T-LAK cell-originated protein kinase. repress stem cell properties and radioresistance in non-
J Ginseng Res. 2016;40(4):400-408. small cell lung cancer. Apoptosis. 2023;28(3-4):397-413.
doi: 10.1016/j.jgr.2016.03.007 doi: 10.1007/s10495-022-01789-y
45. Huang H, Mu X, Deng J, Xiao S, Luo Z, Chen G. Solvation 56. Herbert KJ, Puliyadi R, Prevo R, et al. Targeting TOPK
free energy for selection of an aqueous two-phase system: sensitises tumour cells to radiation-induced damage
Case in paeonol extraction from cortex moutan. ACS by enhancing replication stress. Cell Death Differ.
Omega. 2022;7(35):30920-30929. 2021;28(4):1333-1346.
doi: 10.1021/acsomega.2c02693 doi: 10.1038/s41418-020-00655-1
46. Zhao S, Cui J, Cao L, et al. Xanthohumol inhibits non- 57. Sanmamed MF, Chen L. A Paradigm shift in cancer
small cell lung cancer via directly targeting T-lymphokine- immunotherapy: From enhancement to normalization. Cell.
activated killer cell-originated protein kinase. Phytother Res. 2018;175(2):313-326.
2023;37(7):3057-3068. doi: 10.1016/j.cell.2018.09.035
doi: 10.1002/ptr.7799 58. Liu M, Yu X, Qu C, Xu S. Predictive value of gene databases
47. Lu S, Ye L, Yin S, et al. Glycyrol exerts potent therapeutic in discovering new biomarkers and new therapeutic targets
effect on lung cancer via directly inactivating T-LAK cell- in lung cancer. Medicina (Kaunas). 2023;59(3):547.
originated protein kinase. Pharmacol Res. 2019;147:104366. doi: 10.3390/medicina59030547
48. Lu H, Huang Y, Ni X, et al. TOPK promotes the development 59. Li J, Sun H, Fu M, et al. TOPK mediates immune evasion
of psoriasis and worenine alleviates psoriasiform dermatitis of renal cell carcinoma via upregulating the expression of
by inhibiting TOPK activity. J Eur Acad Dermatol Venereol. PD-L1. iScience. 2023;26(7):107185.
2023;38:851-63.
doi: 10.1016/j.isci.2023.107185
doi: 10.1111/jdv.19724
60. Zhou B, Zang R, Zhang M, et al. Identifying novel
49. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy tumor-related antigens and immune phenotypes for
in advanced non-small cell lung cancer: Current advances developing mRNA vaccines in lung adenocarcinoma. Int
and future trends. J Hematol Oncol. 2021;14(1):108. Immunopharmacol. 2022;109:108816.
doi: 10.1186/s13045-021-01121-2 doi: 10.1016/j.intimp.2022.108816
50. Tsao AS, Scagliotti GV, Bunn PA Jr., et al. Scientific advances 61. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics,
in lung cancer 2015. J Thorac Oncol. 2016;11(5):613-638. 2022. CA Cancer J Clin. 2022;72(1):7-33.
doi: 10.1016/j.jtho.2016.03.012 doi: 10.3322/caac.21708
51. Cheng Y, Zhang T, Xu Q. Therapeutic advances in non- 62. Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares
small cell lung cancer: Focus on clinical development of L. Mechanisms of acquired resistance to first- and second-
targeted therapy and immunotherapy. MedComm (2020). generation EGFR tyrosine kinase inhibitors. Ann Oncol.
2021;2(4):692-729. 2018;29(Suppl 1):i10-i19.

Volume 3 Issue 2 (2024) 10 doi: 10.36922/gpd.3062